Global Information
회사소개 | 문의 | 비교리스트

세계의 패혈증 진단 검사 시장(2021-2028년)

Global Septicemia Diagnostic Testing Market - 2021-2028

리서치사 DataM Intelligence
발행일 On Demand Report 상품코드 1043579
페이지 정보 영문 180 Pages 배송안내 2일 (영업일 기준)
가격
US $ 4,350 ₩ 5,531,000 PDF & Excel (Single User License)
US $ 4,850 ₩ 6,167,000 PDF & Excel (Multiple User License)
US $ 7,850 ₩ 9,982,000 PDF & Excel (Enterprise License)


세계의 패혈증 진단 검사 시장(2021-2028년) Global Septicemia Diagnostic Testing Market - 2021-2028
발행일 : On Demand Report 페이지 정보 : 영문 180 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

패혈증에는 확정 진단 검사가 없고, 진단에는 감염증이나 장기 기능 장애 증거에 근거한 임상적 판단이 필요합니다.

세계의 패혈증 진단 검사(Septicemia Diagnostic Testing) 시장에 대해 조사분석했으며, 업계 분석, 부문별 시장 분석, 경쟁 구도, 주요 기업 등에 대한 정보를 제공합니다.

목차

제1장 세계의 패혈증 진단 검사 시장 - 조사 방법과 범위

제2장 세계의 패혈증 진단 검사 시장 - 시장의 정의와 개요

제3장 세계의 패혈증 진단 검사 시장 - 개요

제4장 세계의 패혈증 진단 검사 시장 - 시장 역학

  • 시장에 영향을 미치는 요인
    • 성장 촉진요인
    • 성장 억제요인
    • 기회
    • 영향 분석

제5장 세계의 패혈증 진단 검사 시장 - 업계 분석

  • Porter의 산업 분석
  • 공급망 분석
  • 가격 분석
  • 규제 분석
  • 상환 분석
  • 미충족 요구

제6장 세계의 패혈증 진단 검사 시장 - COVID-19 분석

  • 시장에 대한 COVID-19 분석
  • COVID-19 가격 동향
  • 수급 스펙트럼
  • 팬데믹 기간의 시장에 관련된 정부 이니셔티브
  • 제조업체의 전략적 이니셔티브
  • 결론
  • 기타

제7장 세계의 패혈증 진단 검사 시장 - 제품별

  • 서론
  • 기구
  • 혈액 배지
  • 어세이 키트 및 시약
  • 기타

제8장 세계의 패혈증 진단 검사 시장 - 기술별

  • 서론
  • 미생물학
  • 분자진단
  • 면역분석법
  • 기타

제9장 세계의 패혈증 진단 검사 시장 - 검사 유형별

  • 서론
  • 실험실 검사
  • PoC 검사

제10장 세계의 패혈증 진단 검사 시장 - 병원체 별

  • 서론
  • 세균성 패혈증
  • 진균성 패혈증
  • 기타

제11장 세계의 패혈증 진단 검사 시장 - 최종사용자별

  • 서론
  • 클리닉
  • 진단센터
  • 기타

제12장 세계의 패혈증 진단 검사 시장 - 지역별

  • 서론
  • 북미
  • 유럽
  • 남미
  • 아시아태평양
  • 중동/아프리카

제13장 세계의 패혈증 진단 검사 시장 - 경쟁 구도

  • 주요 발전과 전략
  • 기업 점유율 분석
  • 제품 벤치마킹
  • 주목해야 할 주요 기업 리스트
  • 파괴적 기술을 보유한 기업 리스트

제14장 세계의 패혈증 진단 검사 시장 - 기업 개요

  • Diasorin
  • Abbott
  • F. Hoffmann-LA Roche Ltd
  • bioMerieux SA
  • Becton, Dickinson, and Company
  • Bruker Corporation
  • Luminex Corporation
  • Beckman Coulter, Inc.
  • McKesson

제15장 세계의 패혈증 진단 검사 시장 - DataM

LSH 22.01.24

Market Overview

Sepsis is a life-threatening organ dysfunction when the body's immune system attacks its organs and tissues in reaction to an infection. Chronic sickness, a weakened immune system, renal or liver disease, cancer, and serious wounds can all cause it. There is no confirmatory diagnostic test, and sepsis diagnosis requires clinical judgment based on infection and organ dysfunction evidence.

The global septicemia diagnostic testing market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Market Dynamics

Novel technologies for the diagnosis of sepsis are expected to drive market growth.

Nanotechnology-based solutions for clinical difficulties are becoming more widely used, opening up new possibilities in diagnosing and managing critical illnesses, including infections induced by bacteria resistant to antibiotics. Changing the antimicrobial discipline is frequently used in sepsis management for diagnostic, prognostic, monitoring, surrogate, and stratification purposes. Nanotechnology-based biosensors offer a revolutionary diagnostic technique that improves biomarker sensitivity and processing speed without professional abilities. For instance, a few biomarkers, such as CRP, PCT, and Interleukin-6, have been helpful in the clinical diagnosis of sepsis. Moreover, biomarkers have established a new paradigm for developing novel biosensors that can detect the presence of any biomarker in a variety of biological media, including whole blood, plasma, serum, cellular fluid, and others.

Restraint:

The lack of standard protocols and awareness, the high cost of automated diagnostic instruments, the lack of standard protocols and awareness, and the scarcity of experienced healthcare personnel are some factors that the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The SARS-CoV-2 pandemic resulted in a near-global lockdown and moderately influenced the septicemia diagnostic testing industry. One of the primary causes of death in COVID-19 patients is sepsis, which leads to multiorgan failure. The activation of the coagulation system in advanced or severe SARS-CoV-2 infection has been studied in several investigations. Sepsis has a significant mortality rate, showing that it is still one of the leading causes of death worldwide. Sepsis can be caused by various pathogens, including bacteria, fungi, and viruses. Even though bacterial infections were the most common cause of sepsis in these patients, clinical study and identification of viral sepsis are still uncommon. As a result, diagnosis is essential in a pandemic situation where no viable medication for the disease is available on the market.

Additionally, the market faces challenges in manufacturing and delivering testing kits due to an interrupted supply chain. Providing essential services due to lockdowns has reduced supply to the end-users. The pandemic is not likely to have long-term effects on end-users primary growth in the septicemia diagnostic testing market.

Segment Analysis

Blood Culture Media segment is expected to hold the largest market share in septicemia diagnostic testing market.

The blood culture media segment accounted for the largest market share in 2020. It is because blood culture is considered the most convenient and cost-effective mode of testing by clinicians. Moreover, blood tests reveal a lot of information about the body to healthcare providers, ranging from the possibility of infection to the functioning of the body's organs. These are some of the more typical blood tests performed on sepsis-like signs and symptoms patients. None of these tests can diagnose sepsis, but they can assist a doctor in diagnosing it when the results are paired with information about the condition and a physical examination.

For instance, A complete blood count is a standard blood test. It determines, among other things, how many white blood cells are circulating in the circulation. White blood cells (also known as leukocytes) combat bacteria, viruses, and other harmful organisms in the body. A patient with a higher-than-average number of white blood cells (WBCs) in the blood may become infected. However, a low number of WBCs can suggest that the patient is at risk of infection. As a result of the above assertions, the market is predicted to grow in the forecast years.

Geographical Analysis

North America region holds the largest market share in the global septicemia diagnostic testing market

In 2020, North America accounted for the highest revenue share. The incidence of sepsis cases in the United States increases every year due to factors such as an aging population, infections resistant to antibiotics, and higher sepsis risks among persons who have had an organ transplant. For instance, according to the Centers for Disease Control and Prevention (CDC), sepsis has a prevalence of 535 cases per 100,000 person-years in the United States and is on the rise. Moreover, the National Institutes of Health (NIH) funds sepsis research that assesses alternative therapeutic options. The CDC has started a public awareness campaign called "Get Ahead of Sepsis," which aims to protect Americans against the effects of sepsis. This campaign encourages healthcare providers to educate patients, prevent infections, recognize and diagnose sepsis early, and begin treatment as soon as possible.

In addition, the region's well-established healthcare infrastructure has resulted in a rise in modern diagnostic solutions. Furthermore, large competitors on the ground and a favorable reimbursement system in this region encourage market expansion in the forecast period.

Competitive Landscape

Major key players in the septicemia diagnostic testing market are Diasorin , Abbott, F. Hoffmann-LA Roche Ltd, bioMerieux SA, Becton, Dickinson, and Company, Bruker Corporation, Luminex Corporation, Beckman Coulter, Inc. and McKesson. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which contribute to the global growth of the septicemia diagnostic testing market. For instance, Cytovale Inc. and the Biomedical Advanced Research and Development Authority, or BARDA, announced cooperation in April 2020 to increase the use of Cytovale's Rapid Sepsis Diagnostic System for identifying sepsis in patients with probable respiratory infections, such as COVID-19.

Diasorin.:

Overview:

DiaSorin is an international biotechnology company based in Saluggia, Italy, established in 2000. The company focuses on producing molecular diagnostics research and laboratory kits, specializing in the infectious diseases sector with tests that use a variety of matrices such as blood, cerebrospinal fluid, skin, and mucus swabs. It has also been involved in the Life Science industry since July 2021. Saluggia and Gerenzano (Italy), Dietzenbach (Germany), Stillwater, Minnesota (US), and Dartford (UK) are the locations where it is manufactured (UK). Following the purchase of Luminex, the business added five more manufacturing plants in the United States (Austin, Madison, Chicago, and Seattle) and Canada (Toronto).

Product Portfolio:

LIAISON BRAHMS PCT II GEN assay uses chemiluminescence immunoassay (CLIA) technology for the in vitro quantitative determination of Procalcitonin in human serum and plasma specimens. The assay is intended for use, in conjunction with other laboratory findings and clinical assessments, to aid in the risk analysis of critically ill patients for progression of relevant bacterial infections.

Why Purchase the Report?

  • Visualize the composition of the global septicemia diagnostic testing market segmentation by product, technology, testing type, pathogen, end user and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in global septicemia diagnostic testing market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of global septicemia diagnostic testing market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global septicemia diagnostic testing market report would provide an access to an approx.45+ market data table, 40+ figures and 180pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Septicemia Diagnostic Testing Market - By Product

  • Instruments
  • Blood Culture Media
  • Assay Kits and Reagents
  • Others

Global Septicemia Diagnostic Testing Market - By Technology

  • Microbiology
  • Molecular Diagnostics
  • Immunoassays
  • Others

Global Septicemia Diagnostic Testing Market - By Testing type

  • Laboratory Testing
  • PoC Testing

Global Septicemia Diagnostic Testing Market - By Pathogen

  • Bacterial Sepsis
  • Fungal Sepsis
  • Others

Global Septicemia Diagnostic Testing Market - By End user

  • Clinics
  • Diagnostic Centers
  • Others

Global Septicemia Diagnostic Testing Market - By Region

  • North America
  • South America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

1. Global Septicemia Diagnostic Testing Market - Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Septicemia Diagnostic Testing Market - Market Definition and Overview

3. Global Septicemia Diagnostic Testing Market - Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Technology
  • 3.3. Market Snippet by Testing type
  • 3.4. Market Snippet by Pathogen
  • 3.5. Market Snippet by End user
  • 3.6. Market Snippet by Region

4. Global Septicemia Diagnostic Testing Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Novel technologies for the diagnosis of sepsis are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The high cost of automated diagnostic instruments is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Septicemia Diagnostic Testing Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Septicemia Diagnostic Testing Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion
  • 6.7. Others

7. Global Septicemia Diagnostic Testing Market - By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product Segment
  • 7.2. Instruments*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Blood Culture Media
  • 7.4. Assay Kits and Reagents
  • 7.5. Others

8. Global Septicemia Diagnostic Testing Market - By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology Segment
  • 8.2. Microbiology*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Molecular Diagnostics
  • 8.4. Immunoassays
  • 8.5. Others

9. Global Septicemia Diagnostic Testing Market - By Testing Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Testing type
    • 9.1.2. Market Attractiveness Index, By Testing type Segment
  • 9.2. Laboratory Testing*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. PoC Testing

10. Global Septicemia Diagnostic Testing Market - By Pathogen

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen
    • 10.1.2. Market Attractiveness Index, By Pathogen Segment
  • 10.2. Bacterial Sepsis*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 10.3. Fungal Sepsis
  • 10.4. Others

11. Global Septicemia Diagnostic Testing Market - By End user

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.1.2. Market Attractiveness Index, By End user Segment
  • 11.2. Clinics*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 11.3. Diagnostic Centers
  • 11.4. Others

12. Global Septicemia Diagnostic Testing Market - By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Testing type
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Testing type
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Testing type
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Testing type
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Testing type
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

13. Global Septicemia Diagnostic Testing Market - Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking
  • 13.4. List of Key Companies to Watch
  • 13.5. List of Company with disruptive technology

14. Global Septicemia Diagnostic Testing Market- Company Profiles

  • 14.1. Diasorin*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Abbott
  • 14.3. F. Hoffmann-LA Roche Ltd
  • 14.4. bioMerieux SA
  • 14.5. Becton, Dickinson, and Company
  • 14.6. Bruker Corporation
  • 14.7. Luminex Corporation
  • 14.8. Beckman Coulter, Inc.
  • 14.9. McKesson

LIST NOT EXHAUSTIVE

15. Global Septicemia Diagnostic Testing Market - DataM

  • 15.1. Appendix
  • 15.2. About Us
  • 15.3. Contact Us
Back to Top
전화 문의
F A Q